Earle A. Chiles Research Institute is among a handful of centers in the world capable of developing and administering adoptive cell therapy, a highly personalized type of immunotherapy. We are recruiting adult patients with certain solid cancers for a phase I clinical trial to evaluate the safety and effectiveness of gene-engineered, adoptively transferred T cells.
T cells are a type of immune cell which, under the right circumstances, can recognize and attack cancer cells. T-cell transfer therapy is a form of adoptive cell therapy that enhances T cells in a laboratory so they can find and destroy cancer cells more effectively. While T-cell transfer therapy has been successful in treating some blood cancers, many solid cancers do not respond and continue to grow.
Our researchers are studying whether T-cell transfer therapy and genetic engineering can shrink solid cancers that are resistant to therapy. In their landmark New England Journal of Medicine article Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer, Rom Leidner, M.D., Eric Tran, Ph.D., and Providence colleagues provide the world’s first report of metastatic pancreatic cancer regression through T-cell transfer therapy with genetically-engineered T cells.
Drs. Tran and Leidner have opened a phase 1 clinical trial to evaluate this therapy in a small group of patients with solid cancers that are unresponsive to standard care.
Targeting KRAS hotspot for incurable epithelial cancers
Epithelial cancers are carcinomas that originate in the epithelial tissue found in the skin and organs throughout the body. They account for a broad array of the most common solid cancers – including breast, colon and lung – and are responsible for 85% of annual cancer deaths.
In this study known as Hotspot TCR-T, T cells from patients are genetically engineered to express a T-cell receptor (TCR) that redirects the T cells to target a common cancer mutation called a hotspot. One such hotspot is a mutated form of the KRAS oncogene.
In healthy cells, the KRAS protein supports normal cell growth and proliferation. Mutated KRAS variants result in uncontrolled cell growth and are present in 30% of epithelial cancers.
Triple combination therapy
To develop this therapy, T cells are obtained from a patient’s blood. In our Adoptive Cell Therapy Lab, the T cells undergo TCR gene-engineering to target hotspot mutations expressed by the patient’s cancer. Then they are amplified in magnitude and potency, and returned to the patient through intravenous infusion. This therapy is experimental.
This investigator-initiated study is led by Rom Leidner, M.D., medical director, Providence Head and Neck Cancer Program, and Eric Tran, Ph.D., assistant member and leader of the Adoptive Cell Therapy Lab at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon.
Providence Portland Medical Center in Portland, Oregon, is the only location to offer the study.
Get the full details here:
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, with in Vivo CD40 Activation and PD-1 Blockade, for Patients with Incurable Cancers
Up to 24 patients from the United States* will be enrolled to the study. Patients with metastatic or locoregionally advanced epithelial cancers which are considered incurable (have failed prior treatments or are not candidates for surgery) may be eligible.
These include certain cancers of the breast, gastrointestinal tract (colon, stomach, gallbladder, bile ducts, pancreas and liver), lung, prostate and bladder. Patients with melanoma or cancers of the blood, soft tissue (sarcomas) or neurological tissue are not eligible.
To qualify, participants must meet several eligibility criteria, including the following KRAS mutations and human leukocyte antigen (HLA) typing:
KRAS G12V with HLA-A*11:01 or HLA-DRB1*07:01
KRAS G12D with HLA-A*11:01 or HLA-C*08:02
Patients should contact their oncologist to inquire about their KRAS and HLA statuses. To help determine patient eligibility, oncologists can coordinate two required, pre-screening tests:
- Tumor next-generation sequencing (NGS) – KRAS G12D or KRAS G12V mutation
- HLA typing – High Resolution: A, B, C, DRB1, DQB1, DPB1
One lab that offers HLA typing is Kashi Clinical Laboratories. It offers both physician ordering and direct patient ordering. Because the study requires "high resolution" HLA typing, orders must be made by calling: (877) 879-1815 and requesting the “High Resolution Combination: A, B, C, DRB1, DQB1, DPB1".
The cost of these tests is not covered by the Hotspot TCR-T research study and will be the responsibility of the patient or their insurance.
*Participation in this study is limited to patients from the United States. The study is not accepting international patients at this time.
Oncology referral information
To refer patients whose NGS testing and HLA typing match the requirements listed above, oncologists can contact our team by phone or email:
Send an email to CanRsrchStudies@providence.org
We are receiving a high volume of inquiries and responses may be delayed.